A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine.
Using a photochemically driven labeling technique, a Cornell-led research group has devised a way to capture cancer-specific protein-to-protein interactions, which could spawn targeted therapies for prostate and other forms of the disease.
Brain-resident immune cells that have reached an old-age state called “senescence” secrete a protein that causes dysfunction in other brain cells, according to Weill Cornell Medicine researchers, a finding that could shed light on memory loss.
The second season of Research Matters, a Cornell video podcast, drops today, with a way-too-relevant episode on why we don't always do the things we know we should.
Traumatic brain injury in Pakistan is associated with a high risk of death and disability long after the initial injury, even in mild to moderate cases.
The 3,681 first-year students and 603 transfers who begin moving to campus Aug. 17, hail from 49 states plus Washington, D.C., Puerto Rico and American Samoa, and 62 countries.
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial.
Researchers have uncovered how a key Parkinson’s protein shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state.